<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90733">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01932853</url>
  </required_header>
  <id_info>
    <org_study_id>QM-RR-02</org_study_id>
    <nct_id>NCT01932853</nct_id>
  </id_info>
  <brief_title>Association Between Dose Dialysis by Kt and Mortality</brief_title>
  <official_title>Evaluation of the Association of Dialysis Dose Obtained by Kt and Mortality in Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NephroCare Spain</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NephroCare Spain</source>
  <oversight_info>
    <authority>Spain: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess whether patients receiving current recommendations of an
      adequate dialysis dose by Kt adjusted for body surface area improved survival at 24 months
      compared to those who do not get it, as well as assess whether patients receiving a dose
      greater obtain more benefit.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>two years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>two years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Mortality and hospitalization cause</measure>
    <time_frame>two years</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>End Stage Renal Disease</condition>
  <condition>Hemodialysis Patients</condition>
  <arm_group>
    <arm_group_label>Hemodialysis patients</arm_group_label>
    <description>Patients &gt; 18y hemodialysis for at least 6 months at any center of Spain Fresenius Medical Care (FMC) meeting the inclusion criteria.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Study subjects:

        Patients&gt; 18 years in hemodialysis treatment at any FMC center of Spain that meet the
        inclusion criteria.

        Data will be collected according to clinical practice and patients will be categorized
        according to their dose of Kt, along the two years of the study. Will seek the association
        of dialysis dose with mortality and hospitalization
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; 18 years old

          -  &gt; six months on hemodialysis

          -  Receiving 3 sessions of dialysis per week

          -  Having 5 or more valid measures of Kt during the month

        Exclusion Criteria:

          -  active chronic inflammatory diseases

          -  Liver cirrhosis

          -  Neoplasms

          -  Chronic immunosuppression or use of anti-inflammatory
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesc Maduell, MD, Ph</last_name>
    <role>Principal Investigator</role>
    <affiliation>Servei Nefrologia, ICNU, Hospital Clínic.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rosa Ramos, MD, Ph</last_name>
    <phone>913276650</phone>
    <phone_ext>235</phone_ext>
    <email>rosa.ramos@fmc-ag.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Inés Palomares</last_name>
    <phone>913276650</phone>
    <phone_ext>233</phone_ext>
    <email>ines.palomares@fmc-ag.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NephroCare Spain</name>
      <address>
        <city>Madrid</city>
        <zip>28042</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rosa Ramos, MD, Ph</last_name>
      <phone>913276650</phone>
      <phone_ext>235</phone_ext>
      <email>rosa.ramos@fmc-ag.com</email>
    </contact>
    <contact_backup>
      <last_name>Inés Palomares</last_name>
      <phone>913276650</phone>
      <phone_ext>233</phone_ext>
      <email>ines.palomares@fmc-ag.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 27, 2013</lastchanged_date>
  <firstreceived_date>August 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>NephroCare Spain</investigator_affiliation>
    <investigator_full_name>Rosa Ramos</investigator_full_name>
    <investigator_title>MD, Ph</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
